Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial

por Bailey, Simon, André, Nicolas, Gandola, Lorenza, Massimino, Maura, Rutkowski, Stefan, Clifford, Steven C.
Publicado 2022

Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray

por Hacking, James P.R., Thompson, Dean, Schwalbe, Edward C., Clifford, Steven C., Williamson, Daniel
Publicado 2023

SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma

por Mynarek, Martin, Milde, Till, Padovani, Laetitia, Janssens, Geert O., Kwiecien, Robert, Mosseri, Veronique, Clifford, Steven C., Doz, François, Rutkowski, Stefan
Publicado 2021

EMBR-10. INOSITOL TREATMENT INHIBITS MEDULLOBLASTOMA THROUGH SUPPRESSION OF EPIGENETIC-DRIVEN METABOLIC ADAPTATION

por Badodi, Sara, Pomella, Nicola, Zhang, Xinyu, Morrison, Gillian, Pollard, Steve M, Bennett, Christopher D, Clifford, Steven C, Peet, Andrew, Marino, Silvia
Publicado 2021

Amplification and Overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in Medulloblastoma

por Lu, Yuan, Ryan, Sarra L., Elliott, David J., Bignell, Graham R., Futreal, P. Andrew, Ellison, David W., Bailey, Simon, Clifford, Steven C.
Publicado 2009

MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile

por Alaña, Lide, Martin-Guerrero, Idoia, Navajas, Aurora, Zaldumbide, Laura, Mosteiro, Lorena, Schwalbe, Edward C, Hicks, Debbie, Clifford, Steven C, García-Ariza, Miguel
Publicado 2022

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA

por Llargués-Sistac, Gemma, Lindsey, Janet, Swartz, Shanel, Selby, Matthew, Morcavallo, Alaide, Bailey, Simon, Chesler, Louis, Lord, Christopher J, Williamson, Daniel, Clifford, Steven C
Publicado 2020

Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and dea...

por Rogers, Hazel A., Kilday, John-Paul, Mayne, Cerys, Ward, Jennifer, Adamowicz-Brice, Martyna, Schwalbe, Ed C., Clifford, Steven C., Coyle, Beth, Grundy, Richard G.
Publicado 2011

The AHR pathway represses TGFβ-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma

por Sarić, Nemanja, Selby, Matthew, Ramaswamy, Vijay, Kool, Marcel, Stockinger, Brigitta, Hogstrand, Christer, Williamson, Daniel, Marino, Silvia, Taylor, Michael D., Clifford, Steven C., Basson, M. Albert
Publicado 2020

MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse

por Kui, Christopher, Richardson, Stacey, Schwalbe, Edward C, Thompson, Dean, Keeling, Claire, Strathdee, Gordon, Dufour, Christelle, Bailey, Simon, Ramaswamy, Vijay, Clifford, Steven C, Hill, Rebecca M
Publicado 2022

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial

por Goschzik, Tobias, Schwalbe, Edward C, Hicks, Debbie, Smith, Amanda, zur Muehlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Lannering, Birgitta, Pietsch, Torsten, Clifford, Steven C
Publicado 2018

MBRS-33. TEMPORARY RESTORATION OF p53 ACTIVITY DURING FRACTIONATED RADIOTHERAPY IN A GROUP3 MEDULLOBLASTOMA GEMM REPRESENTS A POWERFUL TOOL FOR RADIOBIOLOGY STUDIES

por Morcavallo, Alaide, Mandeville, Henry, Barker, Karen, Richardson, Stacey, Lindsey, Janet, Lockett, Nikita, Boult, Jessica K R, Robinson, Simon P, Oelfke, Uwe, Williamson, Daniel, Clifford, Steven C, Chesler, Louis
Publicado 2020

Acceptance and commitment therapy for young brain tumour survivors: study protocol for an acceptability and feasibility trial

por Malins, Sam, Owen, Ray, Wright, Ingram, Borrill, Heather, Limond, Jenny, Gibson, Faith, Grundy, Richard G, Bailey, Simon, Clifford, Steven C, Lowis, Stephen, Lemon, James, Hayes, Louise, Thomas, Sophie
Publicado 2021

ATRT-25. INTEGRATED QUANTITATIVE SWATH-MS PROTEOMICS ANALYSIS OF ATRTs UNCOVERS NEW THERAPEUTIC OPPORTUNITIES

por Finetti, Martina Anna, Hacking, James, Lishman-Walker, Emma, Synowsky, Silvia A, Crosier, Stephen, Martin, Emmma, Burns, Jess, Shirran, Sally L, Bailey, Simon, Clifford, Steven C, Huang, Paul, Williamson, Daniel
Publicado 2020

How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?

por Bailey, Simon, Davidson, Alan, Parkes, Jeannette, Tabori, Uri, Figaji, Anthony, Epari, Shridar, Chinnaswamy, Girish, Dias-Coronado, Rosaldi, Casavilca-Zambrano, Sandro, Amayiri, Nisreen, Vassal, Gilles, Bouffet, Eric, Clifford, Steven C.
Publicado 2022

Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation

por Chen, Zhuoyao, Ioris, Rafael M., Richardson, Stacey, Van Ess, Ava N., Vendrell, Iolanda, Kessler, Benedikt M., Buffa, Francesca M., Busino, Luca, Clifford, Steven C., Bullock, Alex N., D’Angiolella, Vincenzo
Publicado 2022

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial

por Clifford, Steven C., Lannering, Birgitta, Schwalbe, Ed C., Hicks, Debbie, O' Toole, Kieran, Nicholson, Sarah Leigh, Goschzik, Tobias, zur Mühlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Gustafsson, Göran, Pietsch, Torsten
Publicado 2015

Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study

por Sabel, Magnus, Fleischhack, Gudrun, Tippelt, Stephan, Gustafsson, Göran, Doz, François, Kortmann, Rolf, Massimino, Maura, Navajas, Aurora, von Hoff, Katja, Rutkowski, Stefan, Warmuth-Metz, Monika, Clifford, Steven C., Pietsch, Torsten, Pizer, Barry, Lannering, Birgitta
Publicado 2016

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma

por Adiamah, Magretta, Lindsey, Janet C, Burté, Florence, Kohe, Sarah, Morcavallo, Alaide, Blair, Helen, Hill, Rebecca M, Singh, Mankaran, Crosier, Stephen, Zhang, Tong, Maddocks, Oliver, Peet, Andrew, Chesler, Louis, Hickson, Ian, Maxwell, Ross, Clifford, Steven C
Publicado 2022

Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study

por Hill, Rebecca M, Richardson, Stacey, Schwalbe, Edward C, Hicks, Debbie, Lindsey, Janet C, Crosier, Stephen, Rafiee, Gholamreza, Grabovska, Yura, Wharton, Stephen B, Jacques, Thomas S, Michalski, Antony, Joshi, Abhijit, Pizer, Barry, Williamson, Daniel, Bailey, Simon, Clifford, Steven C
Publicado 2020